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The developmental effects of NMP are well studied in SpragueeDawley rats following oral, inhalation,
and dermal routes of exposure. Short-term and chronic occupational exposure limit (OEL) values were
derived using an updated physiologically based pharmacokinetic (PBPK) model for NMP, along with
benchmark dose modeling. Two suitable developmental endpoints were evaluated for human health risk
assessment: (1) for acute exposures, the increased incidence of skeletal malformations, an effect noted
only at oral doses that were toxic to the dam and fetus; and (2) for repeated exposures to NMP, changes
in fetal/pup body weight. Where possible, data from multiple studies were pooled to increase the pre-
dictive power of the doseeresponse data sets. For the purposes of internal dose estimation, the window
of susceptibility was estimated for each endpoint, and was used in the doseeresponse modeling. A point
of departure value of 390 mg/L (in terms of peak NMP in blood) was calculated for skeletal malforma-
tions based on pooled data from oral and inhalation studies. Acceptable doseeresponse model ﬁts were
not obtained using the pooled data for fetal/pup body weight changes. These data sets were also assessed
individually, from which the geometric mean value obtained from the inhalation studies (470 mg*hr/L),
was used to derive the chronic OEL. A PBPK model for NMP in humans was used to calculate human
equivalent concentrations corresponding to the internal dose point of departure values. Application of a
net uncertainty factor of 20e21, which incorporates data-derived extrapolation factors, to the point of
departure values yields short-term and chronic occupational exposure limit values of 86 and 24 ppm,
respectively.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
N-methyl-2-pyrrolidone (NMP; CASRN ¼ 872-50-4) was
developed as an alternative to chlorinated solvents such as meth-
ylene chloride due to its lower volatility, ﬂammability and toxicity.
It is widely used in the petrochemical industry in the recovery of
pure hydrocarbons (HSDB, 2014). As a solvent, it is used in cleaning,
electronics, agricultural, and coatings industries. It is also anC.R. Kirman).
Inc. This is an open access article uexcipient in drug formulations designed for oral and dermal de-
livery (Jouyban et al., 2010). Because of its widespread use in
multiple industries, there is a potential for worker exposures to
NMP (Meier et al., 2013; Bader et al., 2006).
NMP has a robust toxicological database, with developmental
effects identiﬁed as the most sensitive endpoint for human health
risk assessment (OECD, 2007; Poet et al., 2010; USEPA, 2015). The
parent compound, rather than a metabolite, has been identiﬁed as
the likely developmental toxin based on the results of in vivo and
in vitro studies of rats exposed to NMP and its major metabolites
(Saillenfait et al., 2007a; Flick et al., 2009). Currently, neither NIOSH
nor ACGIH have derived occupational exposure limits (OELs) fornder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
T.S. Poet et al. / Regulatory Toxicology and Pharmacology 76 (2016) 102e112 103NMP. The AIHA (1998) derived an 8-h Workplace Environmental
Exposure Level (WEEL) of 10 ppm for NMP. This value is consistent
with the 8-h TWA OEL values of 10 and 20 ppm derived by the
European Commission (SCOEL, 2007) and Germany (DFG, 2014),
respectively. DIVM calculated derived no effect levels (DNELs) of 10
and 5 mg/m3 (2.5 and 1.2 ppm) for non-pregnant and pregnant
workers, respectively (RIVM, 2013). More recently, advisory boards
to the California Division of Occupational Safety and Health
considered establishing an 8-h TWA Permissible Exposure Limit
(PEL) for NMP (COSHSB, 2013). After several years of discussion, the
Health Expert Advisory Committee (HEAC) was unable to reach
consensus on a single value for a health-based PEL. Subsequently,
the Feasibility Advisory Committee (FAC) proposed a PEL of 1 ppm,
the low end of the health-based PELs considered by the HEAC,
based on analytical and economic feasibility. This proposal was
subsequently accepted by the California Occupational Safety and
Health Standards Board (COSHSB, 2013).
A physiologically based pharmacokinetic (PBPK) model has
previously been developed to describe the toxicokinetics of NMP in
rats and humans (Poet et al., 2010). The goal of the work presented
here is to update the existing PBPK model for NMP and apply it in
the derivation of occupation exposure limits (OELs) for NMP using
the best available science and risk assessment practices.
2. Methods
2.1. PBPK model development and application
A PBPKmodel has been developed to describe the toxicokinetics
of NMP in rats and humans (Poet et al., 2010). For this work, it was
determined that minor reﬁnements to the model would enhance
its functionality and accuracy; model details are described in
Supplement A1. A summary of the data sets used to calibrate and
validate the PBPKmodel is provided in Table 1. The overall structure
of the model remains the same as described in Poet et al. (2010),
however parameterization of the model has been revised for both
rats and humans using a more systematic treatment of the available
data sets, particularly for characterizing inter-individual variation
in humans, as summarized brieﬂy below.
For the rat model, hepatic metabolism terms (Vmax and Km) for
the oxidation of NMP to 5-HNMP were re-optimized to ﬁt available
plasma clearance data following i.v. exposures (Payan et al., 2002),
and were validated against similar data collected by Wells and
Digenis (1988). To improve model ﬁts to rat data collected
following oral exposures to NMP (Ghantous, 1995; Midgely et al.,
1992), the model was revised to include rate constants for two
absorption pathways, absorption in the stomach (KAS ¼ 1.5 h1)
and absorption in the small intestines (KSI¼ 0.006 h1). These data
indicate NMP is well absorbed in the gastrointestinal tract (recov-
ery of radiolabeled NMP ranged from 90 to 98% (mean ¼ 94% for
single high or low doses given to male or female rats Ghantous,
1995). For dermal exposures, the dermal permeability (Kp) term
that was previously estimated from in vitro data for rat skin (Payan
et al., 2003) has instead been estimated from in vivo data for rats
from the same study, resulting in a value (Kp ¼ 4.3  103 cm/h)
optimized from in vivo data that falls within the range of in vitro
values obtained for NMP (2e7.7  103 cm/h) (Payan et al., 2003).
No changes were made regarding uptake of NMP following
inhalation exposures in rats. (Inhalation bioavailability is set at
100%.) However, it should be noted the study used to parameterize
the inhalation model (Ghantous, 1995) utilized nose-only expo-
sures, which may not account for potential multiple routes of
exposure associated with whole-body inhalation exposures. Tissue
partition coefﬁcient values remain the same as published for rats in
Poet et al. (2010), and the saturable urinary elimination pathway,was determined to be more complex than needed, and has been
replaced with a simpliﬁed ﬁrst order pathway.
For the human model, emphasis was placed on characterizing
inter-individual variation in metabolism (VmaxC, Km; VmaxC2,
Km2) following inhalation exposures to NMP (Bader and van Thriel,
2006). This study is unique in that it provides blood and urine data
for parent chemical andmetabolite, following three exposure levels
(2.5, 10, 20 ppm or 10, 40, 80 mg/m3), and multiple time points, all
of which are provided separately for individual volunteers. Dermal
uptake of NMP fromvapor and liquid phases was assessed using the
data of Akesson and Paulson (1997) and Akesson et al. (2004),
respectively. Tissue partition coefﬁcients (PCs) were calculated
from the tissue:saline PCs reported by Poet et al. (2010). Like the rat
model, urinary elimination in humans was simpliﬁed to be ﬁrst-
order; urinary rate constants were obtained by ﬁtting to the data
of Bader and van Thriel (2006).
The revised PBPKmodel was applied tomultiple steps in the OEL
calculation process for NMP:
 Route-to-Route Extrapolation of Dose-Response Data e Develop-
mental toxicity studies for NMP are available for inhalation
(Saillenfait et al., 2003; Solomon et al., 1995), oral (Saillenfait
et al., 2002; Thornton, 1999), and dermal routes of exposure
(Becci et al., 1982). The revised rat PBPK model (Supplement A1)
was used to estimate the internal doses of NMP expected under
the conditions of these developmental toxicity studies. These
internal dose estimates were then used to assess the dos-
eeresponse relationships for keyendpoints to estimate a point of
departure (POD). Because the doseeresponse datawere assessed
in terms of internal dose, data for routes other than inhalation
(oral and dermal) were used to support the OEL derivation.
 Characterization of Uncertainty in Estimating Internal Doses for
Whole-Body Rat Inhalation Studies e The inhalation component
of the rat PBPK model was parameterized using a toxicokinetic
study that used “nose-only” exposures (Ghantous, 1995).
Because the inhalation toxicity studies for NMP (Saillenfait et al.,
2003; Solomon et al., 1995) involved “whole-body” exposures to
NMP in air, some uncertainty is introduced in applying the
parameterized model to the assessment. By not including other
potential routes of exposure associated with whole-body ex-
posures (dermal absorption of vapors; ingesting of NMP adsor-
bed to fur during grooming), the parameterized PBPK model
may underestimate actual exposures to NMP under whole-body
exposure conditions. To characterize the relative importance of
this area of uncertainty, additional analyses were performed to
assess the contributions required from these other routes to
achieve route-to-route concordance of doseeresponse data.
 Interspecies Extrapolation e The revised human PBPK model
(Supplement A1) was used to estimate the external occupa-
tional exposures corresponding to the internal rat POD values.
 Characterization of Human Variation in Toxicokinetic Factors e
The revised human PBPK model was applied to individual time-
course data for NMP (Bader and van Thriel, 2006) to characterize
variation in internal dose estimates in humans following ex-
posures to a deﬁned concentration of NMP in air.
2.2. OEL derivation
Short-term and chronic OEL values were derived for NMP using
the following equation:
OEL ¼ PODHEC=UFT
where, OEL ¼ Occupational Exposure Limit (ppm);
PODHEC ¼ Human equivalent concentration for the point of
Table 1
Summary of pharmacokinetic data sets available for NMP and their application to model development.
Species Data use
category for
PBPK model
Study Route Exposure range Speciﬁc model parameters (if applicable)a
Rat Calibration Payan et al.
(2002)
iv 0.1e500 mg/kg Metabolic rate constants (VmaxC ¼ 9 mg/h/kg^ 0.75, Km ¼ 225 mg/L for NMP;
VmaxC2 ¼ 0.09 mg/h/kg 0^.75, Km2 ¼ 4.9 mg/L for 5HNMP) were optimized to match
behavior of NMP in plasma (Fig. A1-1) and ﬁrst order urinary elimination rates for
5HNMP
Midgley et al.
(1992)
Oral Gavage 104 mg/kg Oral absorption terms (KAS ¼ 1.5 h1, KAI ¼ 0.85 h1, KSI ¼ 0.006 h1), ﬁrst order
transfer from stomach to liver, stomach to intestine and intestine to liver) were
optimized to match model predictions to NMP plasma data (Fig. A1-2)
Payan et al.
(2003)
Dermal (liquid) 44e700 ml neat Dermal absorption (Kp ¼ 4.3  103 cm/h) was optimized to match behavior of NMP
in plasma (Fig. A1-3)
Validation Wells and
Digenis
(1988)
iv 45 mg/kg Metabolic rate constants VmaxC, Km, VmaxC2, Km2) were validated based on
predictions of the model to NMP in plasma (Fig. A1-1)
Ghantous
(1995)
Oral Gavage 54 mg/kg Oral absorption terms (KAS, KAI, KSI) were validated by comparingmodel predictions
to data for NMP in plasma (Fig. A1-2)
Ghantous
(1995)
Inhalation, nose only 10, 100 ppme6 h Inhalation validated by comparing model predictions to data for NMP in plasma
(Fig. 1). 100% bioavailability was assumed
Payan et al.
(2003)
Dermal (in vitro) Neat NMP Dermal absorption (Kp ¼ 4.3  103 cm/h) was validated by comparison to in vitro
results, which are in close agreement (2e7.7  103 cm/h)
Human Calibration Bader and van
Thiel, 2006
Inhalation 2.5, 10, 20 ppm (10,
40, and 80 mg/m3)
Metabolic rate constants (VmaxC ¼ 44 mg/h/kg^ 0.75, Km ¼ 68 mg/L;
VmaxC2 ¼ 4.5 mg/h/kg^0.75, Km2 ¼ 61 mg/L) were optimized to match the behavior
of NMP and 5HNMP in plasma (Figs. 2, A1-4)
Akesson and
Paulsson
(1997)
Inhalation þ Dermal
(vapor)
2.5, 6, 13 ppm (10,
24, 53 mg/m3)
Dermal vapor absorption (Vapor Kpb ¼ 22 cm/h) was optimized to match NMP the
behavior of NMP in plasma following dermal and inhalation exposure (Fig. A1-5)
Akesson et al.
(2004)
Dermal (liquid) 300 mg (neat, 50%
solution)
Dermal liquid absorption (Liquid Kpb ¼ 2.0  103 cm/h) was optimized to match
plasma 5HNMP following exposures to either neat NMP or NMP diluted in aqueous
solution (50%) (Fig. A1-6)
Validation Xiaofei et al.
(2000)
Inhalation þ dermal
(vapor)
0.14e0.42 ppm
(from dosimeter)
Occupational exposure, Dosimeter data and presumptive NMP splatter was used to ﬁt
the worker and observer data (Fig. A1-7)
HLS (2002) Dermal (in vitro) Neat NMP Dermal absorption (Kp) was validated by comparison to in vitro results, which are in
close agreement (2.7  103 cm/h vs. 2.2  103 cm/h)
a Values provided reﬂect those derived in Appendix A1. Alternative values for some parameters are also provided in Appendix A2 (see text for discussion).
b Kp is the permeability coefﬁcient for NMP. Kp from different phases (i.e., liquid or vapor) are related. For simplicity, different Kp were optimized from the different phases,
but a single Kp could be used with a modifying factor to account for air/water partitioning.
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product of individual uncertainty factors for interspecies variation
(UFa), intraspecies variation (UFh), LOAEL-to-NOAEL (UFl),
subchronic-to-chronic extrapolation (UFs), and database de-
ﬁciencies (UFd). Because of potential overlap in these uncertainty
factors, the total uncertainty factor value is typically capped at a
value of 3000 in deriving reference values (USEPA, 2002). The
values selected for each uncertainty factor are discussed in the
results section for each OEL.
Derivation of short-term and chronic OELs for NMP is a multi-
step process, requiring a consideration of multiple options at each
step, as described below.2.2.1. Data set/endpoint selection
The developmental effects of NMP have consistently been
identiﬁed as the most sensitive endpoint for human health risk
assessment (OECD, 2007; USEPA, 2015; Poet et al., 2010), and
therefore serve as the focus of this assessment. NMP is a data-rich
chemical for which there are multiple developmental toxicity
studies available in rats, including those for inhalation (Saillenfait
et al., 2003; Solomon et al., 1995), oral (Saillenfait et al., 2002;
Thornton, 1999), and dermal routes of exposure (Becci et al.,
1982). The developmental toxicity of NMP has also been evalu-
ated in rabbits (OECD, 2007). Key data sets for the effects of NMP on
fetal/pup body weight changes and on skeletal malformations from
studies conducted in rats were assembled and are summarized in
Table 2. In addition, the ﬁrst row of this table provides historical
control values for fetal/pup body weights from previous studies
(Saillenfait et al., 1999a,b, 2002, 2003, 2007a,b, 2008, 2009, 2011a,b,
2013).Skeletal malformations were selected as the most appropriate
basis for the short-term OEL, under an assumption that the effects
observed could occur following a single exposure event during
gestation. Other endpoints, such as fetal resorptions/mortality,
delayed ossiﬁcation, were not considered further because (a) they
were observed at concentrations similar to or higher than those
producing skeletal malformations; (b) they exhibited generally
high or variable background rates, (c) the effects of NMP were not
consistent across the data sets, and/or (d) the endpoints are likely
related to reductions in fetal bodyweight used to derive the chronic
OEL. Skeletal malformations were observed in the oral study
(Saillenfait et al., 2002), but not the inhalation studies (Saillenfait
et al., 2003; Solomon et al., 1995). Inspection of internal doses of
NMP for these studies indicate that the internal exposures for the
inhalation studies are lower than the internal doses associatedwith
effects in the oral studies, consistent with doseeresponse concor-
dance across studies (i.e., combined data sets can be described by a
single doseeresponse curve). Therefore the oral and inhalation
studies of Saillenfait et al. were pooled (combined across studies
prior to doseeresponse modeling). Pooling the data sets provides
broader coverage of the range of observation, and supports the
appropriateness of route-to-route extrapolation required to use
this endpoint for OEL derivation.
The relative potency of chemicals in producing fetal bodyweight
changes following single and repeated exposures was assessed by
van Raaij et al. (2003). The authors concluded, “… when fetal body
weight reduction occurs only at doses that are maternally toxic and
other effects on the fetus are limited to retarded skeletal ossiﬁcation,
the effects are probably caused by repeated exposure and are unlikely
to occur from a single exposure at the same dose” (van Raaij et al.
Table 2
Summary of key data sets for the developmental effects of NMP.
Reference Exposure regimen (gestation
period coverage)
Administered dose (mg/kg-day) or
concentration (ppm)
Internal dosea Fetal/pup
weight
Skeletal
malformation
Average daily AUC,
GD13-20 (hamg/L)
Average peak,
GD7-20 (mg/L)
n Mean ± SD
(g)
Litter
incidence
Fetal
incidence
Saillenfait
historical
controls
NA NA 0 0 604 5.65 ± 0.35 NC NC
Saillenfait et al.
(2002)
Gavage (GD6-20) 0 0 0 21 5.73 ± 0.50 0/20 0/133
125 1290 106 21 5.59 ± 0.22 0/21 0/138
250 2820 219 24 5.18 ± 0.35 0/24 0/152
500 6430 461 25 4.02 ± 0.21 12/25 14/155
750 10,500 717 8 3.01 ± 0.39 3/5 5/9
Saillenfait et al.
(2003)
Inhalation, 6 h/d (GD6-20) 0 0 0 24 5.67 ± 0.37 0/24 0/167
30 158 15.0 20 5.62 ± 0.36 0/19 0/126
60 322 30.3 19 5.47 ± 0.25 0/19 0/133
120 668 61.9 25 5.39 ± 0.45 0/25 0/150
Becci et al. (1982) Dermal, 8 h/d (GD6-15) 0 0 0 24 3.45 ± 0.20 0/24 0/187
75 340 68 22 3.49 ± 0.24 0/22 0/108
237 1230 187 23 3.54 ± 0.29 0/23 0/192
750 3910 470 22 2.83 ± 0.39 11/22 14/156
Solomon et al.
(1995)
Inhalation, 6 h/d (GD1-20) 0 0 0 39 7.48 ± 0.71 1/14 1/205
10 52 4.9 16 7.03 ± 0.70 NA NA
51 272 25 15 7.14 ± 0.69 NA NA
116 643 85 22 6.66 ± 0.62 0/13 0/185
Thornton (1999) Feed (GD1-20) 0 0 0 25 6.7 ± 0.65 NA NA
50 591 NC 25 6.9 ± 0.39 NA NA
160 1960 NC 24 6.8 ± 0.77 NA NA
500 7920 NC 22 5.3 ± 0.78 NA NA
N ¼ number of live litters; NC ¼ not calculated; NA ¼ not assessed.
a The PBPKmodel for NMP, as modiﬁed in Appendix A, was used to predict rat internal doses for NMP in blood over the window of susceptibility as determined in Appendix
B. Values rounded to 3 signiﬁcant ﬁgures.
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NMP, acute exposures are not expected to produce changes in fetal
body weight in the same manner as repeated exposures. As an
endpoint associated with cumulative exposure, changes in fetal/
pup body weight associated with NMP were considered an
appropriate endpoint for the chronic OEL. Five data sets for fetal/
pup body weight changes in Sprague Dawley rats that included all
three routes of exposure were assessed separately and pooled
(combined prior to doseeresponse modeling) (Table 2).
2.2.2. Dose measure estimation
Because the developmental effects of NMP have been attributed
to the parent chemical, rather than one of its metabolites
(Saillenfait et al., 2007; Flick et al., 2009), internal dose measures
based on the parent chemical are considered to be suitable candi-
dates. For this assessment, PBPK model predictions for NMP in
maternal blood were considered to be appropriate since: (1) con-
centrations of NMP inmaternal blood can be predictedwith greater
conﬁdence than in fetal tissues (lacking data); and (2) fetal tissue
concentrations of NMP are expected to be directly proportionate to
maternal blood concentrations of NMP. Two measures of internal
dose, as estimated using the revised rat PBPK model (Supplement
A) were used in this assessment: (1) the predicted daily peak
concentration of NMP in maternal blood, averaged over the expo-
sure period, was used to assess skeletal malformations, since this
endpoint was only observed with oral exposures (whose time
proﬁle is more peaked than expected for inhalation); and (2) the
predicted area-under-the-curve (AUC) for NMP in maternal blood
was used to assess fetal body weight changes, since this endpoint
was considered to be the result of cumulative exposure. Because
the doseeresponse data will be assessed in terms of internal dose,
data for routes other than inhalation (oral and dermal) can also be
used to support the inhalation OEL derivation.
Because the study designs for the key developmental toxicitystudies are varied and provide coverage for different portions of the
gestation period (early, mid, and late), the pooled data sets for NMP
can support an evaluation of the window of susceptibility for each
endpoint. To evaluate an early-stage window of susceptibility, daily
AUC values were averaged across an exposure window deﬁned as
gestation day 1 (GD1) through gestation day X (GDX), where X was
allowed to vary from days 2e20 (Supplement B). Similarly, to
evaluate a late-stage window, internal dose was averaged across an
exposurewindowdeﬁned as GDX-GD20, where X is allowed to vary
from days 1e19. After each adjustment in the exposure window,
that average internal dose was calculated and the correlation co-
efﬁcient for consistency in the doseeresponse relationship across
all ﬁve data sets was recorded. The window of susceptibility was
identiﬁed as the time period for which optimal correlation across
data sets was achieved. For benchmark dose (BMD) modeling, daily
internal dose values were then averaged across the window of
susceptibility identiﬁed for each endpoint.
2.2.3. Dose-response model selection
A large number of BMD evaluations were performed for this
assessment. The details of these evaluations are provided in
Supplement B, and are summarized below. BMD modeling was
performed using USEPA's BMD Software package (version 2.5), in a
manner consistent with USEPA guidelines (USEPA, 2012). Dichot-
omous models were used to ﬁt doseeresponse data for skeletal
malformations, and continuous models were used to ﬁt dos-
eeresponse data for fetal/pup body weight changes. Incidence data
for fetal malformations were assessed two different ways: (1) on an
affected litter basis (using data from column 8 in Table 2); and (2)
on an affected fetus basis (using data from column 9 in Table 2). The
best ﬁtting model was selected based on a consideration of Akaike
information criterion (AIC; lower value indicates a better ﬁt), chi-
square goodness of ﬁt p-value (higher value indicates a better ﬁt),
ratio of the BMC:BMCL (lower value indicates less model
Fig. 1. Plasma NMP following inhalation exposure of rats to NMP:
diamonds ¼ arithmetic mean (100 pm, Ghantous, 1995), error bars ¼ standard devi-
ation, solid line ¼ PBPK model predictions.
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2.2.4. Point of departure (POD)/human equivalent concentration
(HEC) calculation
The selection of an appropriate benchmark response rate for
skeletal malformations needs to take into consideration the basis
(affected litter or fetus) on which the data were assessed. In sum-
marizing a series of published assessments of developmental
toxicity data (Faustman et al., 1994; Allen et al., 1994a,b; Kavlock
et al., 1995), when the doseeresponse data are modeled on an
affected fetus basis, the BMDL05 value was approximately equal to
the estimated NOAEL value. However, when the data were assessed
on an affected litter basis, the BMDL10 was 2e3 times lower than
the estimated NOAEL value (USEPA, 2012). Assessing the data on an
affected fetus basis using a nested doseeresponse model is
preferred, since it can account for potential litter effects (e.g.,
affected fetuses concentrated in one or more litters). Unfortunately,
sufﬁcient data are not available from the key studies to permit the
application of a nested doseeresponse model. However, visual in-
spection of the data available from Saillenfait et al. (2002) and Becci
et al. (1982) indicate potential litter effects for skeletal malforma-
tions are likely negligible (14 affected fetuses spread over 12 litters
from dams exposed to 500 mg/kg-day by the oral route; 5 affected
fetuses spread over 3 litters (out of 5 total litters) from dams
exposed to 750mg/kg-day by the oral route; and 14 affected fetuses
spread over 11 litters from dams exposed to 750 mg/kg-day by the
dermal route; Table 2). For this reason, it is reasonable to assume
the affected fetuses are evenly spread between litters, and the
assessment of the data on an affected fetus basis can be considered
a reasonable estimate of the results that would be obtained from
the application of a nested model. For fetal malformations, the in-
ternal dose corresponding to a 5% increase in extra risk (BMD05)
and its 95% lower conﬁdence limit (BMDL05) were considered
appropriate POD values based on fetal incidence. For comparison
purposes, the internal dose corresponding to a 10% increase in extra
risk (BMD10) and its 95% lower conﬁdence limit (BMDL10) were
calculated from the data based on litter incidence.
For fetal body weight changes, the internal dose corresponding
to a decrease in the mean response equivalent to one standard
deviation (SD) in unexposed animals (BMCSD) and its 95% lower
conﬁdence limit (BMCLSD) were calculated. Since the control SD for
pup/fetal body weight are typically between 5% and 10% of control
body weights (Table 2), BMDLSD values are expected to fall be-
tween alternative benchmark response rates (BMDL05 and
BMDL10). The BMDLSD is considered to be an appropriate POD for
weight changes reported in developmental toxicity studies based
on precedent assessments for other chemicals posted on USEPA's
IRIS database (RfD for tetrahydrofuran, RfC for methanol, RfC for
cyclohexane; RfD for phenol) (USEPA, 2014).
The updated version of the human PBPK model for NMP
(Supplement A1) was used to estimate HEC values that correspond
to the rat POD internal dose values obtained from BMD modeling.
HEC values were based on simulations conducted for a pregnant
woman (8 h/day, 5 days/week), with and without the contribution
of dermal absorption of NMP vapors. To evaluate the impact of
model parameterization of the human PBPK model on the assess-
ment, an alternative set of human model parameters was used for
comparison purposes. Speciﬁcally, USEPA's modiﬁed version of the
Poet et al. (2010) model used to support the TSCA risk assessment
for NMP (USEPA, 2015; Supplement A2) was included in this
assessment. This model differs slightly from the primary version of
the model used (Supplement A1) in that the parameters were
optimized to the low concentration data of Bader and van Thriel
(2006), while the mid and high concentration data were not
used. This was done because the intended use of USEPA's model inthe TSCA risk assessment (USEPA, 2015) was to predict potential
hazards in humans exposed low concentration to NMP. Because the
human PBPK model was used to estimate the human equivalent
concentration (HEC) associated with rodent points of departure,
which are reported at high concentrations (i.e., above those
examined by Bader and van Thriel, 2006), the primary version of
the human PBPK model is based upon all of the data (low, mid, and
high concentrations) from Bader and van Thriel (2006)
(Supplement A1). The impact of alternative PBPK modeling pa-
rameterizations on the resulting POD values presented and
discussed.
2.2.5. Uncertainty factor selection
Individual uncertainty factors (UFa, UFh, UFl, UFs, UFd) were
deﬁned based upon available information for NMP and current risk
assessment practices. The default value of 10 for UFh was assumed
to comprise of equivalent parts for toxicokinetic and toxicodynamic
factors (100.5 or ~3.16). The default value for toxicokinetic variation
was replaced by a data-derived extrapolation factor (DDEF; USEPA,
2011) based upon application of the revised human PBPK modeling
to toxicokinetic data for individual volunteers (Bader and van
Thriel, 2006). The DDEF value was derived assuming internal
doses for NMP are approximately normally distributed for a given
exposure using the one-tailed z0.05 quantile for a normal distribu-
tion, 1.645; i.e. with DDEFhTK ¼ (1 þ CV) * 1.645, where CV is the
coefﬁcient of variation estimated from the individual volunteer
internal doses, 95% of a healthy worker population is estimated to
have internal doses less than this factor above the mean.
For this assessment, all internal dose POD values fall within the
range of linear toxicokinetics for NMP, therefore the application of
uncertainty factors either before or after calculating human
equivalent concentrations results in the same OEL value (e.g., this is
not always the case when nonlinear toxicokinetics are involved).
3. Results
3.1. PBPK model
The PBPK model for NMP in rats and humans was revised
(Supplement A). Example comparisons between model predictions
and measured time-course data following inhalation exposures are
provided in Fig. 1 for rats (Ghantous, 1995) and in Fig. 2 for indi-
vidual human volunteers (Bader and van Thriel, 2006). PBPK model
predictions of internal doses for individual volunteers are sum-
marized in Table 3. Addition ﬁgures and details for the PBPKmodel,
Fig. 2. Model ﬁts to individual voluenteers (Bader and van Thriel, 2006), triangles ¼ 20 ppm, circles ¼ 10 ppm, diamonds ¼ 2.5 ppm, lines ¼ PBPK model predictions.
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predictions (peak and AUC for NMP in blood) from the rat PBPK
model for NMP under the conditions of the developmental toxicity
studies are summarized in Table 2.3.2. Short term OEL
Results of the window of susceptibility evaluation for peak NMP
and skeletal malformations support the use of a window ofTable 3
Internal dose measures for individual volunteers exposure to NMP (Bader and van Thrie
Volunteer Weight (kg) BMI Peak (mg/L)
10 mg/m3 40 mg/m
1 75 22.9 0.23 0.94
10 72 24.3 0.17 0.69
14 80 23.4 0.19 0.78
17 102 28.3 0.15 0.60
4 80 23.9 0.25 1.0
12 65 23.0 0.15 0.63
16 78 23.6 0.18 0.75
25 80 24.0 0.24 0.98
Mean 0.20 0.80
SD 0.04 0.16
CV 0.21 0.20susceptibility that essentially covers the entire gestation period
(Supplement B; Fig. B-2). This result was interpreted as an acute
exposure of sufﬁcient intensity occurring at any time during
gestation could result in skeletal malformations. Exposures aver-
aged over gestation days 7e20 (GD7-20) provided the best corre-
lation with skeletal malformations (r2 ¼ 0.999 for data points with
non-zero response values). Changing the start of the averaging
period to anywhere from GD6 to GD9 also yielded excellent cor-
relations (r2 > 0.98). Daily average peak values on GD7-20 forl, 2006).
AUC (mg/L-h)
3 80 mg/m3 10 mg/m3 40 mg/m3 80 mg/m3
1.9 1.7 7.0 14
1.4 1.1 4.7 9.5
1.6 1.3 5.5 11
1.2 0.99 4.1 8.3
2.1 2.0 8.2 17
1.3 1.0 4.2 8.4
1.5 1.3 5.2 10
2.0 1.8 7.5 15
1.6 1.4 5.8 12
0.34 0.39 1.6 3.3
0.21 0.28 0.27 0.28
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umn 5 in Table 2). Using these doses, the dichotomous Hill model
provided the best overall ﬁt to the skeletal malformations data set
(Supplement B; Table B-1). POD values for skeletal malformation
expressed in terms of peak NMP in maternal rat blood are provided
in Table 4. The POD value of 390 mg/L (BMDL05, fetal incidence
basis) was selected for deriving the short-term OEL since fetal
incidence is preferred, and because the potential for litter effects is
low as previously discussed. This value is within approximately 30%
of the POD value obtained assessing the data on a litter basis
(310 mg/L). Using revised PBPK model for NMP in humans
(Supplement A), two sets of human equivalent concentrations
(HECs) were calculated for each rat internal dose POD (Table 5). HEC
values corresponding to a peak concentration of NMP in blood of
390 mg/L were calculated to be 2400 ppm for inhalation exposures
only, and 1700 ppm for inhalation and dermal vapor exposures
combined, when it was assumed that 30% of total skin surface area
was uncovered for vapor absorption.
Uncertainty factor values for the short term OEL are based on
the following considerations. Because a PBPK model was used for
interspecies extrapolation, the uncertainty for interspecies varia-
tion (UFa) is reduced from the default value of 10e3.16 (100.5) to
account for potential interspecies variation in toxicodynamics.
Typically, the default uncertainty factor for intraspecies variation in
humans (UFh) is 10, a value derived from the equivalent contri-
bution of 3.16 (100.5) for its toxicokinetic (tk) and toxicodynamic
(td) components. However, based on PBPK modeling of individual
data (Fig. 2), the peak concentrations for a given exposure level
were determined to have a coefﬁcient of variation of approximately
0.21 (Table 3). This information can be used to replace the default
value for UFh toxicokinetics with a date-derived extrapolation
factor (DDEF; USEPA, 2011). Assuming a normal distribution in a
healthy worker population, a DDEF of 2.0 (1.21  1.645, rounded to
two signiﬁcant ﬁgures) is considered to be sufﬁcient for the tox-
icokinetic component to be protective of 95% of a healthy worker
population, yielding a net UFh of 6.3 [2.0 (tk)  3.16 (td)] for UFh.
The available studies for NMP (Table 2) were considered to provide
excellent coverage of the window of susceptibility during gestation
for the endpoints of interest, and therefore a value of 1 is consid-
ered appropriate for UFs (i.e., no need for any duration adjustment).
Because BMD methods were incorporated into the assessment, a
value of 1 is considered appropriate for UFl (i.e., there is no need for
adjustment for use of a LOAEL value). The database for the devel-
opmental toxicity of NMP is robust. The doseeresponse assessment
conducted here incorporates data from ﬁve studies across three
routes of exposure for fetal/pup body weight (Table 2). For this
reason, a value of 1 is considered appropriate for UFd. Based on
these individual uncertainty factor values, a total uncertainty factor
of 20 (3.16  3.16  2.0) is considered appropriate for calculating
the short-term OEL for NMP.
For skeletal malformations, application of a total uncertainty
factor of 20 to the PODHEC values yielded short-term OEL values ofTable 4
Points of departure for skeletal malformations.
Data set (basis) BM
Combined Saillenfait et al. (2002, 2003)/Becci et al. (1982) (Litter incidence) Dic
Combined Saillenfait et al. (2002, 2003)/Becci et al. (1982) (Fetal incidence) Mu
a Comparison of BMD model ﬁts provided in Appendix B, Table B-1. Values expressed
b Value selected for short-term OEL calculation.120 ppm for inhalation exposures alone, and 86 ppm for inhalation
and dermal vapor exposures combined (Table 5), with preference is
given to the lower value of 86 ppm.
3.3. Chronic OEL
Results of the window of susceptibility evaluation for AUC and
fetal/pup body weight effects support the use of a late-gestation
window of susceptibility (Supplement B; Fig. B-1). Exposures
averaged over late-gestation (GD13-20) correlate better with body
weight response (r2¼ 0.84) than do exposures averaged over early-
gestation (r2 < 0.70) or over the entire gestation period (r2 ¼ 0.70).
This result is biologically plausible given that fetal weight gain is
greatest towards the end of gestation (Fig. B-2). Daily average AUC
values on GD13-20 for all 5 studies ranged from 52 to
10,600 mg * h/L (column 4 in Table 2).
None of the available doseeresponse models provided an
acceptable ﬁt to the pooled data set for fetal/pup body weight
changes (goodness of ﬁt p-value <0.1; Supplement B; Table B-2).
Although several doseeresponse models appeared to describe the
general behavior of the pooled data set, visual inspection reveals
considerable scatter in the data (Supplement B; Fig. B-4). For this
reason, BMD modeling of individual data sets was adopted instead.
The best-ﬁtting doseeresponse models for each data set, and
resulting POD values are identiﬁed in Table 6. POD values calculated
for fetal body weight changes are very similar to those calculated
for values based on pup body weight changes (geometric means of
1200 and 1300 mg * h/L, respectively), which suggest that
combining these PODs is appropriate. However, POD values calcu-
lated for inhalation studies appear to be signiﬁcantly lower than
those calculated for oral/dermal exposures (geometric means of
470 and 2400 mg * h/L, respectively), which suggest there is an
apparent difference in potency between inhalation exposures and
other routes of exposure. For this reason, combining POD values
across routes of exposure may not be appropriate, but is included
for comparison purposes. The geometric mean POD value
(470 mg * h/L) for inhalation studies was selected as the basis for
the chronic OEL. This POD corresponds to human equivalent con-
centrations of 630 ppm for inhalation exposures only and 490 ppm
for inhalation and dermal vapor exposures combined (Table 5).
Uncertainty factor values (UFa, UFs, UFl, and UFd) used for the
chronic OEL are the same as described above for the short-term
OEL. With respect to UFh, based on PBPK modeling of individual
data (Fig. 2), AUC values for a deﬁned external concentration were
determined to have a coefﬁcient of variation of approximately 0.28
(Table 3). Under an assumption that internal doses of NMP in a
healthyworker population is approximately normally distributed, a
factor of 2.1 (1.28  1.645, rounded to two signiﬁcant ﬁgures) is
considered to be sufﬁcient for the toxicokinetic component to be
protective of 95% of a healthy worker population, yielding a value of
6.6 for UFh. This value is slightly different from the one used for the
short-term OEL due to slight differences in variation in theD modela BMR Internal dose
(average peak
NMP in blood
GD7-20, mg/L)
BMD BMDL
hotomous Hill (AIC ¼ 77.8; p-value ¼ 1.000) 10% 380 310
ltistage (AIC ¼ 203.7; p-value ¼ 1.000) 5% 410 390b
to two signiﬁcant ﬁgures.
Table 5
Occupational exposure limit values for NMP.
OEL Endpoint Data set POD
type
Point of departure Uncertainty
factorb
OEL (ppm)
Internal dose HEC (ppm,
inhalation
only)a
HEC (ppm, inhalation
& dermal vapor)a
Inhalation
only
Inhalation &
dermal vapor
Short-
term
Skeletal
malformations
Saillenfait et al. (2002, 2003)
Combined (fetus basis)
BMDL05 Average Peak GD7-
20 ¼ 390 mg/L
2400 (1600) 1700 (1300) 20 120 (80) 86 (65)
Chronic Fetal/pup
body weight
Geometric mean inhalation
Studies
BMDLSD Average AUC GD13-
20 ¼ 470 mgah/L
630 (460) 490 (350) 21 30 (22) 24 (17)
a Calculated using the revised human PBPK model (Appendix A1), expressed to two signiﬁcant ﬁgures. Values in parentheses reﬂect HEC predictions using USEPA's pa-
rameters for the human PBPK model used to support the TSCA risk assessment for NMP (Appendix A2).
b Calculated as the product of uncertainty factors for variation interspecies toxicodynamics (3.16), intraspecies toxicokinetics (2.0 or 2.1), and intraspecies toxicodynamics
(3.16).
Table 6
Points of departure for fetal/pup body weight changes.
Data set Route Endpoint BMD modela Internal dose (average daily
AUC GD14-20, mgah/L)
BMDSD BMDLSD
Saillenfait et al. (2002) Oral Fetal BW Exponential (AIC ¼ 107.2; p-value ¼ 0.425) 1800 1400
Saillenfait et al. (2003) Inhalation Exponential (AIC ¼ 83.8; p-value ¼ 0.760) 850 530
Becci et al. (1982) Dermal Power (AIC ¼ 136.7; p-value ¼ 0.371) 3700 2300
Solomon et al. (1995) Inhalation Pup BW Exponential (AIC ¼ 28.1; p-value ¼ 0.139) 610 420
Thornton (1999) Oral Polynomial (AIC ¼ 19.9; p-value ¼ 0.382) 5900 4100
Geometric mean (fetal BW studies) 1800 1200
Geometric mean (pup BW studies) 1900 1300
Geometric mean (oral & dermal studies) 3400 2400
Geometric mean (inhalation studies) 720 470b
Geometric mean (all studies) 1800 1200
a Comparison of BMD model ﬁts provided in Table B-2.
b Value selected for chronic OEL calculation.
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on these individual uncertainty factor values, a total uncertainty
factor of 21 (3.16  3.16  2.1) is considered appropriate for
calculating a chronic OEL for NMP. Application of an uncertainty
factor of 21 yielded chronic OEL values of 30 ppm for inhalation
exposures alone, and 24 ppm for inhalation and dermal vapor ex-
posures combined (Table 5).
4. Discussion/conclusions
An assessment was conducted for NMP that resulted in the
calculation of a short-term OEL value of 86 ppm based on skeletal
malformations in rats. This value reﬂects BMD modeling of pooled
data sets across routes of exposure (oral, dermal, and inhalation)
using a PBPK-derived internal dose measure. An assessment was
also conducted for NMP that resulted in the calculation of a chronic
OEL value of 24 ppm based on fetal/pup body weight changes. BMD
modeling of the pooled data sets for body weight decrements
across routes of exposure yielded unacceptable p-values. Instead,
the chronic OEL for NMP is based upon data from inhalation studies
only, since the internal doses of NMP appear to be more potent for
inhalation exposures than internal doses arising from other routes
of exposure. These OEL values are expected to be protective of the
developmental effects of NMP observed in rats. In addition, these
exposures are not expected to be associated with potential irrita-
tion in workers. Bader et al. (2006) reported that exposures to
concentrations of 20 ppm (and peak exposures to 40 ppm) did not
result in irritation, as indicated by a lack of exposure-related
changes in eye blink rates, nasal ﬂow rates, and breathing rates in
human volunteers.
The inability to achieve route-to-route concordance in the
doseeresponse relationships for fetal/pup body weight changesfollowing inhalation exposures may be due in part to the uncer-
tainty associated with the PBPK model's reliance upon a nose-only
exposure study for model parameters. Speciﬁcally, air exposures to
rats were parameterized in the PBPK model from a nose-only
exposure study (Ghantous, 1995) and subsequently used in this
assessment to predict internal doses resulting from whole-body
exposures to rats (Saillenfait et al., 2003; Solomon et al., 1995).
Therefore in rats, model predictions for whole-body exposures do
not include any contributions from dermal uptake of vapors or oral
uptake via grooming. If the model is signiﬁcantly underestimating
the true internal dose of NMP when additional pathways are
considered (dermal absorption of vapor; ingestion of NMP adsor-
bed to fur while grooming), then inhalation exposures will erro-
neously appear more potent than exposure via other routes. In
addition, rats in these studies are under more stress than other
studies, and no food or water is available during the exposure
period, so stress likely plays a part in the apparent sensitivity in
this exposure group. The evaluation conducted in Supplement B
suggests if the total internal dose for whole-body exposures (i.e.,
sum of inhalation, dermal vapor, and oral pathway contributions)
in rats was 3.3-fold higher than predictions based on the inhala-
tion route alone, concordance across routes of exposure would be
achieved for the doseeresponse curves. This is consistent with
human exposures, where, the combined contributions from
inhalation and dermal absorption of vapor (whenwearing trousers
and short-sleeved shirts) to the internal dose were 1.5- to 1.7-fold
higher than that from inhalation alone (Bader et al., 2008),
grooming in rats could account for a small increase in rats as well.
McDougal et al. (1990) reported that the dermal permeability
coefﬁcients for organic chemical vapors were 2- to 4-times greater
in rats compared to humans. However, this experiment was con-
ducted in animals with clipped fur, and therefore the impact of fur
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vapors on to fur, this pathway has been shown to be potentially
signiﬁcant for other chemicals, including 2-butoxyethanol (Poet
et al., 2003) and 1,1,2,2-tetrachloroethane (Gargas and Andersen,
1989). Additional research on the relative contribution of these
pathways for NMP could be used to support route-to-route
concordance for the inhalation data sets, which if achieved
would support a chronic OEL value that is approximately 5- to 6-
fold higher than derived here (based upon the ratio of POD
values for the pooled data set to those for inhalation data sets;
Supplement B, Table B-2). Another potential explanation for the
greater potency of inhaled NMP in producing fetal body weight
changes may be related to the prolonged exposures of rats to NMP
vapors, whose odor is reported to be moderately annoying at high
concentrations (Bader and van Thriel, 2006), and a factor that may
contribute to maternal stress, which in turn can affect fetal
growth.
The human PBPK model was ﬁt to toxicokinetics data from in-
dividual volunteers (Bader and van Thriel, 2006). On average, the
data are consistent with linear toxicokinetics across the range of
exposures (2.5e20 ppm), which is consistent with the study au-
thors' ﬁndings of statistically signiﬁcant linear correlations be-
tween external NMP concentrations in air and peak concentrations
of NMP and its metabolites in blood and urine. In all cases, the
model was well-within 2-fold of measured peak blood values,
demonstrating good ﬁts. However, inspection of data from indi-
vidual volunteers reveals some differences in toxicokinetic
behavior (Supplement A). These individual differences served as
the primary motivation for applying the PBPK model to individual
volunteer data. Introduction of more complex toxicokinetics (e.g.,
metabolic inhibition) was not required to achieve the model ﬁts
shown in Fig. 2. A rationale for why deviation from linear kinetics
was observed in some individuals (approximately half; Supplement
A2) but not others is not apparent. Any apparent variations in
toxicokinetic behaviormay be due in part to the greater uncertainty
associated with the toxicokinetic data collected at the lowest con-
centration that are impacted to a greater extent by the limit of
detection, rather than evidence of more complex toxicokinetics for
NMP. It is also possible that factors other than metabolism (e.g.,
differences in breathing rates between treatment days/groups)
contribute to the behavior noted in the data.
Conﬁdence in the PBPK modeling used to support this assess-
ment is medium to high. Dose measures for NMP in maternal blood
were used as surrogates for doses of NMP delivered to the fetus,
since: (1) greater conﬁdence is placed in using the PBPK model to
predict concentrations in maternal blood rather fetal tissue con-
centrations; and (2) fetal tissue concentrations are expected to be
proportionate to maternal blood concentrations (i.e., driven by
tissue partitioning). High conﬁdence is given to the rat PBPK model
in predicting internal doses following oral gavage, inhalation (nose-
only), and dermal exposures to NMP. Medium conﬁdence is given
to the rat model in predicting internal doses following inhalation
(whole-body) exposures due to uncertainty in the contribution of
dermal vapor and grooming pathways, and medium conﬁdence is
given for dietary exposures due to uncertainty in bioavailability of
NMP from feed (no data). High conﬁdence is given to the human
PBPK model in predicting internal doses following inhalation and
dermal (vapor and liquid) exposures to NMP, based upon the
availability of multiple data sets and the quality of the ﬁts to the
data (within a factor of 2 for each data set; Fig. 2). Medium conﬁ-
dence is given to predicting internal human doses following oral
exposures to NMP (no data available, therefore predictions require
assuming human absorption kinetics are the same as observed in
rats), however this was not required for OEL derivation.
For each step in the OEL derivation process, a number ofalternative options are available. The impact of many alternatives
on the resulting OEL values is discussed below.
 Alternative Data Sets e For skeletal malformations, POD values
based upon the Saillenfait et al. (2002) alone are essentially
identical to those obtained for the pooled data set (Saillenfait
et al., 2002, 2003; Becci et al., 1982) (Supplement B; Table B-
1). For fetal/pup body weight changes, POD values based upon
the inhalation toxicity studies (Saillenfait et al., 2003; Solomon
et al., 1995) are approximately 2.3- to 8.5-fold lower than
those calculated from oral and dermal toxicity studies
(Saillenfait et al., 2002; Becci et al., 1982; Thornton, 1999), and
therefore the decision to rely on inhalation studies only for the
chronic OEL value may be viewed as health protective
(Supplement B; Table B-2). Inclusion of historical control data in
modeling the Saillenfait et al. (2003) inhalation study resulted in
a POD values that were slightly higher (~30%) than those ob-
tained using concurrent controls, therefore reliance upon con-
current controls in this assessment is also considered health
protective.
 Alternative Human PBPK Model Parameters e For the purposes of
comparison, USEPA's revised human PBPK model used to sup-
port the TSCA risk assessment for NMP (Supplement A2) was
used to calculate alternative HEC values (Table 5; values in pa-
rentheses). In general, HEC values calculated using the USEPA
version of the model were very similar (within 24e33%) but
slightly lower than those calculated here. Based on this com-
parison, the impact of alternative strategies to model parame-
terization by ﬁtting the available human data (all concentration
data vs. low concentration data) on the resulting OEL values is
relatively small.
 Alternative Dose Measures e For skeletal malformations, daily
peak values averaged over the window of susceptibility (GD7-
20) are generally similar (within 5%) to daily peak values aver-
aged over the entire gestation period tested (GD6-20). For fetal/
pup body weight changes, daily AUC values averaged over the
window of susceptibility (GD13-20) are generally similar
(within a factor of 2) to daily AUC values averaged over the
entire gestation period. The largest difference was noted for the
dermal study of Becci et al. (1982), since the study design only
included exposures during a small portion of the window of
susceptibility (i.e., GD 14 and 15).
 Alternative Dose-Response Models e For skeletal malformations
assessed in terms of fetal incidence, models providing an
acceptable ﬁt (p-value >0.1) provided POD values that are very
similar (within 5%) to those obtained using the dichotomous Hill
model (Supplement B; Table B-1). For fetal/pup body weight
changes, models providing an acceptable ﬁt (p-value > 0.1)
provided POD values that are very similar (within 5%) to those
obtained by the dichotomous exponential model (Supplement
B; Table B-2).
 Alternative Points of Departure e For skeletal malformations and
fetal/pup body weight changes, use of alternative benchmark
response rates (5%, 10%) results in POD values that are similar
(within a factor of 2) of those presented in Table 5.
 Alternative Human Equivalent Concentrations e For both end-
points, humanHEC values were calculated for the rat POD values
with and without the contribution from the dermal vapor
pathway (Table 5). Inclusion of the dermal vapor pathway
resulted in HEC values for the POD that are approximately 40%
lower than calculated for inhalation alone. The decision to rely
on OEL values that include the dermal vapor pathway in
humans, while ignoring the contribution of this pathway in rats,
may serve to overestimate the potency of NMP, and therefore
may be considered health protective.
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adopted for all uncertainty factors except for intraspecies vari-
ation (UFh). For UFh, the default value of 10 (comprised of values
of 3.16 each for toxicokinetic and toxicodynamic factors) was
replaced by a value of 6.3e6.6 (2.0e2.1 for toxicokinetic factors;
3.16 for toxicodynamic factors) based upon the toxicokinetic
data of Bader and van Thriel (2006). Application of a default
value for UFh, would result in OEL values that are approximately
40% lower than calculated in Table 5. However, a value of
6.3e6.6 for UFh is considered to be sufﬁciently protective for a
population of healthy adult workers.
 Data Limitations/Gaps e The rat and human PBPK models for
NMP were developed for non-pregnant conditions, but were
applied to predicting internal doses of NMP during pregnancy in
both species. Although changes in physiology (e.g., additional
tissue compartments, growth) are accounted for by the model,
there are insufﬁcient data to account for potential changes in
NMP metabolism that may occur in both species during preg-
nancy. Cytochrome P450 CYP2E1 plays an important role in the
initial oxidation of NMP in rats, and to a lesser extent in humans
(Ligocka et al., 2003). In rats, CYP2E1 along with several other
isozymes were decreased in late gestation (day 19), some iso-
zymes were decreased in mid-gestation, and some were un-
changed throughout gestation (He et al., 2005). Additional
information regarding the speciﬁc isozymes responsible for
human metabolism of NMP, as well as information regarding
potential changes during gestation would help improve conﬁ-
dence in the PBPK model predictions. In the absence of such
information, it is assumed that: (1) any potential changes in
humans are qualitatively and quantitatively similar to those
occurring in rats, and (2) the relative difference in NMP meta-
bolism between rats and humans under non-pregnancy condi-
tions approximates the relative difference in NMP metabolism
under pregnancy conditions.
A revised PBPK model was used to describe differences between
rats and humans with respect to the toxicokinetics of NMP, and was
subsequently used to support the derivation of OEL values. In so
doing, the uncertainty associated with inter- and intra-species ex-
trapolations is reduced, allowing for a reduction in the default value
for UFa from 10 to 3.16, and the default value for UFh from 10 to
6.3e6.6. Despite resulting in higher OEL values (24 and 86 ppm),
conﬁdence remains high that these values are sufﬁciently protec-
tive of developmental toxicity in worker populations, particularly
given the conservative assumptions used in this analysis.
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